应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
ADTX Aditxt, Inc.
休市中 07-02 16:00:00 EDT 延时
资讯
新帖
简况
Aditxt, Inc 高管 Adam Nunes 增持7340178股并减持5120480股
公告助手 · 06-25
Aditxt, Inc 高管 Adam Nunes 增持7340178股并减持5120480股
Ignite Proteomics宣布启动万人前瞻性肿瘤登记研究,评估功能性蛋白质组学在癌症疗法选择中的应用
美股速递 · 06-08
Ignite Proteomics宣布启动万人前瞻性肿瘤登记研究,评估功能性蛋白质组学在癌症疗法选择中的应用
Aditxt任命Jeffrey M. Busch为临时首席执行官,其曾为股东创造约8.5%股息回报的10亿美元级纽交所企业创始人兼前CEO
美股速递 · 06-01
Aditxt任命Jeffrey M. Busch为临时首席执行官,其曾为股东创造约8.5%股息回报的10亿美元级纽交所企业创始人兼前CEO
ADiTx Therapeutics宣布1股并27股的反向拆股,将于2026年5月18日开盘时生效
美股速递 · 05-14
ADiTx Therapeutics宣布1股并27股的反向拆股,将于2026年5月18日开盘时生效
ADiTx Therapeutics收购Ignite Proteomics,破解癌症治疗关键难题:优化疗法选择
美股速递 · 03-13
ADiTx Therapeutics收购Ignite Proteomics,破解癌症治疗关键难题:优化疗法选择
ADiTx Therapeutics (纳斯达克: ADTX) 宣布1比8合股 将于2026年3月9日开盘时生效
美股速递 · 03-05
ADiTx Therapeutics (纳斯达克: ADTX) 宣布1比8合股 将于2026年3月9日开盘时生效
加载更多
公司概况
公司名称:
Aditxt, Inc.
所属市场:
PINK LIMITED
上市日期:
--
主营业务:
Aditxt, Inc.于2017年9月28日根据特拉华州法律注册成立。其使命是通过将高度集中的行业转型为社会所有和引导的生态系统,重新定义健康创新发现、开发和应用的方式,从而提升人类福祉。公司最初专注于一种名为ADI/Adimune的免疫调节技术,旨在延长器官移植患者的生命并提高其生活质量。此后,公司不断拓展其创新产品组合和子公司,同时持续评估各种有前景的健康创新技术。
发行价格:
--
{"stockData":{"symbol":"ADTX","market":"US","secType":"STK","nameCN":"Aditxt, Inc.","latestPrice":0.005145,"timestamp":1783022400000,"preClose":0.005075,"halted":0,"volume":105463756,"delay":15,"changeRate":0.013793103448275985,"floatShares":815200,"shares":815900,"eps":-1380.7628,"marketStatus":"休市中","change":0.00007,"latestTime":"07-02 16:00:00 EDT 延时","open":0.0053,"high":0.0066,"low":0.0046,"amount":579050.812119,"amplitude":0.394089,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1380.7628,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"listingDate":1593489600000,"exchange":"PINK LIMITED","adjPreClose":0.005075,"volumeRatio":0},"requestUrl":"/m/hq/s/ADTX","defaultTab":"news","newsList":[{"id":"1183913351","title":"Aditxt, Inc 高管 Adam Nunes 增持7340178股并减持5120480股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183913351","media":"公告助手","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183913351?lang=zh_cn&edition=full","pubTime":"2026-06-25 05:15","pubTimestamp":1782335711,"startTime":"0","endTime":"0","summary":"Aditxt, Inc (股票代码: ADTX) 的10%大股东 Adam Nunes 于2026年6月18日增持了7,340,178股普通股,交易价格为每股0.013美元。随后,他在2026年6月22日减持了5,120,480股普通股,交易价格为每股0.018美元。这些交易可能会对市场情绪产生一定影响,需要投资者们保持关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Aditxt, Inc 高管 Adam Nunes 增持7340178股并减持5120480股","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131244796","title":"Ignite Proteomics宣布启动万人前瞻性肿瘤登记研究,评估功能性蛋白质组学在癌症疗法选择中的应用","url":"https://stock-news.laohu8.com/highlight/detail?id=1131244796","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131244796?lang=zh_cn&edition=full","pubTime":"2026-06-08 20:16","pubTimestamp":1780920977,"startTime":"0","endTime":"0","summary":"Ignite Proteomics公布了一项前瞻性肿瘤登记研究计划,拟纳入10,000名患者,旨在评估功能性蛋白质组学在癌症治疗方案选择中的实际应用价值。该大规模注册研究将系统性地收集真实世界数据,以深入分析基于蛋白质功能特征的检测方法如何优化临床治疗决策,并探索其在提升患者疗效与生存结局方面的潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190255329","title":"Aditxt任命Jeffrey M. Busch为临时首席执行官,其曾为股东创造约8.5%股息回报的10亿美元级纽交所企业创始人兼前CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=1190255329","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1190255329?lang=zh_cn&edition=full","pubTime":"2026-06-01 20:17","pubTimestamp":1780316235,"startTime":"0","endTime":"0","summary":"Aditxt, Inc. 已任命杰弗里·M·布施为临时首席执行官。布施先生是一位经验丰富的企业领导者,他曾创立并领导一家在纽约证券交易所上市、市值达10亿美元的企业,并为股东带来了约8.5%的股息回报。这一任命标志着公司领导层进入新的过渡阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165402862","title":"ADiTx Therapeutics宣布1股并27股的反向拆股,将于2026年5月18日开盘时生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1165402862","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165402862?lang=zh_cn&edition=full","pubTime":"2026-05-14 20:15","pubTimestamp":1778760920,"startTime":"0","endTime":"0","summary":"ADiTx Therapeutics(纳斯达克股票代码:ADTX)宣布,其1股合并为27股的反向股票拆分计划,将于2026年5月18日市场开盘交易时正式生效。\n此项举措将显著提升公司每股股票的交易价格。反向拆股完成后,公司已发行普通股的数量将按比例大幅减少,而股东所持股票的总价值在理论上将保持不变。公司此举通常旨在满足交易所的最低股价要求,或提升其在投资者眼中的形象。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ADTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189339932","title":"ADiTx Therapeutics收购Ignite Proteomics,破解癌症治疗关键难题:优化疗法选择","url":"https://stock-news.laohu8.com/highlight/detail?id=1189339932","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189339932?lang=zh_cn&edition=full","pubTime":"2026-03-13 20:19","pubTimestamp":1773404375,"startTime":"0","endTime":"0","summary":"ADiTx Therapeutics宣布完成对Ignite Proteomics的战略收购,旨在攻克癌症临床治疗中的核心瓶颈——个体化疗法优选难题。此次并购将通过整合双方在生物标志物检测与蛋白质组学分析领域的技术优势,为肿瘤患者提供更精准的治疗方案决策支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118817402","title":"ADiTx Therapeutics (纳斯达克: ADTX) 宣布1比8合股 将于2026年3月9日开盘时生效","url":"https://stock-news.laohu8.com/highlight/detail?id=1118817402","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118817402?lang=zh_cn&edition=full","pubTime":"2026-03-05 21:33","pubTimestamp":1772717585,"startTime":"0","endTime":"0","summary":"ADiTx Therapeutics (纳斯达克: ADTX) 公布,其1比8的反向股票分割计划已确定于2026年3月9日交易日开盘时正式生效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aditxt.com","description":"Aditxt, Inc.于2017年9月28日根据特拉华州法律注册成立。其使命是通过将高度集中的行业转型为社会所有和引导的生态系统,重新定义健康创新发现、开发和应用的方式,从而提升人类福祉。公司最初专注于一种名为ADI/Adimune的免疫调节技术,旨在延长器官移植患者的生命并提高其生活质量。此后,公司不断拓展其创新产品组合和子公司,同时持续评估各种有前景的健康创新技术。","exchange":"PINK LIMITED","name":"Aditxt, Inc.","nameEN":"Aditxt, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aditxt, Inc.(ADTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aditxt, Inc.(ADTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aditxt, Inc.,ADTX,Aditxt, Inc.股票,Aditxt, Inc.股票老虎,Aditxt, Inc.股票老虎国际,Aditxt, Inc.行情,Aditxt, Inc.股票行情,Aditxt, Inc.股价,Aditxt, Inc.股市,Aditxt, Inc.股票价格,Aditxt, Inc.股票交易,Aditxt, Inc.股票购买,Aditxt, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aditxt, Inc.(ADTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aditxt, Inc.(ADTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}